315 related articles for article (PubMed ID: 11171285)
1. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans.
Böger RH; Lentz SR; Bode-Böger SM; Knapp HR; Haynes WG
Clin Sci (Lond); 2001 Feb; 100(2):161-7. PubMed ID: 11171285
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
3. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid.
Usui M; Matsuoka H; Miyazaki H; Ueda S; Okuda S; Imaizumi T
Clin Sci (Lond); 1999 Mar; 96(3):235-9. PubMed ID: 10029559
[TBL] [Abstract][Full Text] [Related]
4. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine.
Stühlinger MC; Oka RK; Graf EE; Schmölzer I; Upson BM; Kapoor O; Szuba A; Malinow MR; Wascher TC; Pachinger O; Cooke JP
Circulation; 2003 Aug; 108(8):933-8. PubMed ID: 12912818
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
Stühlinger MC; Stanger O
Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
[TBL] [Abstract][Full Text] [Related]
6. [Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options].
Sydow K; Böger RH
Z Kardiol; 2001 Jan; 90(1):1-11. PubMed ID: 11220081
[TBL] [Abstract][Full Text] [Related]
7. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins.
Sydow K; Schwedhelm E; Arakawa N; Bode-Böger SM; Tsikas D; Hornig B; Frölich JC; Böger RH
Cardiovasc Res; 2003 Jan; 57(1):244-52. PubMed ID: 12504835
[TBL] [Abstract][Full Text] [Related]
8. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia.
Doshi S; McDowell I; Goodfellow J; Stabler S; Boger R; Allen R; Newcombe R; Lewis M; Moat S
Metabolism; 2005 Mar; 54(3):351-60. PubMed ID: 15736113
[TBL] [Abstract][Full Text] [Related]
9. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans.
Kanani PM; Sinkey CA; Browning RL; Allaman M; Knapp HR; Haynes WG
Circulation; 1999 Sep; 100(11):1161-8. PubMed ID: 10484535
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link?
Kunz K; Petitjean P; Lisri M; Chantrel F; Koehl C; Wiesel ML; Cazenave JP; Moulin B; Hannedouche TP
Nephrol Dial Transplant; 1999 Aug; 14(8):1934-42. PubMed ID: 10462274
[TBL] [Abstract][Full Text] [Related]
11. Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease.
Ziegler S; Mittermayer F; Plank C; Minar E; Wolzt M; Schernthaner GH
J Clin Endocrinol Metab; 2005 Apr; 90(4):2175-8. PubMed ID: 15634723
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke.
Yoo JH; Lee SC
Atherosclerosis; 2001 Oct; 158(2):425-30. PubMed ID: 11583722
[TBL] [Abstract][Full Text] [Related]
13. Methionine-induced homocysteinemia impairs endothelial function in hypertensives: the role of asymmetrical dimethylarginine and antioxidant vitamins.
Tousoulis D; Bouras G; Antoniades C; Marinou K; Papageorgiou N; Miliou A; Hatzis G; Stefanadi E; Tsioufis C; Stefanadis C
Am J Hypertens; 2011 Aug; 24(8):936-42. PubMed ID: 21490695
[TBL] [Abstract][Full Text] [Related]
14. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
[TBL] [Abstract][Full Text] [Related]
15. Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression.
Gates PE; Boucher ML; Silver AE; Monahan KD; Seals DR
J Appl Physiol (1985); 2007 Jan; 102(1):63-71. PubMed ID: 16946027
[TBL] [Abstract][Full Text] [Related]
16. Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines.
Antoniades C; Tousoulis D; Marinou K; Vasiliadou C; Tentolouris C; Bouras G; Pitsavos C; Stefanadis C
Am J Clin Nutr; 2006 Oct; 84(4):781-8. PubMed ID: 17023704
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients.
Ducloux D; Ruedin C; Gibey R; Vautrin P; Bresson-Vautrin C; Rebibou JM; Chalopin JM
Nephrol Dial Transplant; 1998 Nov; 13(11):2890-3. PubMed ID: 9829496
[TBL] [Abstract][Full Text] [Related]
18. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy.
Chambers JC; McGregor A; Jean-Marie J; Obeid OA; Kooner JS
Circulation; 1999 Mar; 99(9):1156-60. PubMed ID: 10069782
[TBL] [Abstract][Full Text] [Related]
19. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1997 Dec; 20(12):1880-6. PubMed ID: 9405911
[TBL] [Abstract][Full Text] [Related]
20. Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia.
Magné J; Huneau JF; Borderie D; Mathé V; Bos C; Mariotti F
Amino Acids; 2015 Sep; 47(9):1975-82. PubMed ID: 25792109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
